Octozi provides a Generative AI platform designed to automate and accelerate clinical development workflows for biopharma sponsors. The platform uses advanced machine learning analytics for real-time data cleaning, review, and early safety signal detection across clinical trial data. This automation helps increase speed to market while ensuring data quality, security, and regulatory compliance throughout Phase I-IV trials.
Funding
$150K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The life sciences industry faces significant challenges in data cleaning and regulatory submissions due to manual processes, leading to inefficiencies, high costs, and prolonged timelines. These manual workflows are prone to errors and can cause substantial delays in clinical development.
Solution
Octozi offers a platform leveraging custom-built large language models (LLMs) to automate data cleaning and regulatory submission workflows within the pharmaceutical and biotechnology sectors. By applying generative AI and advanced machine learning analytics, Octozi accelerates clinical development, reduces errors, and lowers costs. The platform is designed to handle the needs of biotech startups, large pharma companies, and contract research organizations (CROs) across Phase I-IV trials and various therapeutic areas. Octozi's solution ensures data remains secure and private, without sharing or distributing it to third parties.
Target Audience
Octozi's primary customers include pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) involved in clinical development.
Features
- Custom-developed LLMs specifically tuned for clinical development and regulatory requirements
- Real-time data cleaning using AI models with clinical and trial-specific context
- Scalable and extensible platform suitable for biotech startups, large pharma, and CROs
- Support for Phase I-IV trials across a broad range of therapeutic areas
- Secure and private data handling, ensuring data is not shared with third parties